Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Memphasys Ltd ( (AU:MEM) ) has shared an announcement.
Memphasys has signed a five-year commercial supply agreement with Centro Fertilita Assistita (CFA) Italia, one of Italy’s largest private IVF groups, marking its first commercial contract in mainland Europe and a key step in its global rollout of the Felix sperm isolation system. The deal includes minimum purchase commitments of 7,500 Felix cartridges over the term, valued at about €525,000 (~A$925,000), with CFA already placing an initial order for 500 cartridges ahead of CE Mark approval, providing near-term revenue and validating demand for the technology and the company’s direct sales model. Leveraging CFA’s extensive network of IVF clinics in a large and growing Italian fertility market, the agreement establishes a pathway to recurring revenue, potential volumes beyond the contracted minimums, and broader European expansion once regulatory clearance is achieved.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an ASX-listed medical technology company focused on reproductive health, developing and commercialising its Felix automated sperm isolation system for use in in vitro fertilisation (IVF) procedures. The company targets major global IVF markets, pursuing a direct commercialisation strategy through partnerships with leading fertility clinics and networks across regions including Europe, Japan, India and the Middle East.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.07M
Learn more about MEM stock on TipRanks’ Stock Analysis page.